A9010
Ethyl arachidate
≥99%
Synonym(s):
Ethyl eicosanoate, Ethyl ester of eicosanoic acid, Arachidic acid ethyl ester
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C22H44O2
CAS Number:
Molecular Weight:
340.58
NACRES:
NA.25
PubChem Substance ID:
UNSPSC Code:
12352211
MDL number:
Product Name
Ethyl arachidate, ≥99%
InChI
1S/C22H44O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h3-21H2,1-2H3
SMILES string
CCCCCCCCCCCCCCCCCCCC(=O)OCC
InChI key
YBKSMWBLSBAFBQ-UHFFFAOYSA-N
biological source
synthetic (organic)
assay
≥99%
form
solid
functional group
ester
lipid type
omega FAs
shipped in
ambient
storage temp.
−20°C
Quality Level
Related Categories
Application
- Optimizing the Design of Blood-Brain Barrier-Penetrating Polymer-Lipid-Hybrid Nanoparticles for Delivering Anticancer Drugs to Glioblastoma.: This study explores the development of nanoparticles that can cross the blood-brain barrier to deliver anticancer drugs directly to glioblastoma, utilizing ethyl arachidate in their composition to enhance drug encapsulation and targeting (Ahmed et al., 2021).
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Samara R Alves Rico et al.
Nanoscale, 9(30), 10701-10714 (2017-07-06)
A unique class of diruthenium(ii,iii) metallodrugs containing non-steroidal anti-inflammatory drug (NSAID), Ru
Samara Rodrigues Alves et al.
Journal of inorganic biochemistry, 205, 110984-110984 (2020-01-14)
Novel formulations of diruthenium(II,III)-NSAID (NSAID, non-steroidal anti-inflammatory drug) metallodrugs encapsulated into biocompatible terpolymer-lipid nanoparticles (TPLNs) to target glioblastoma cancer were developed. The nanoformulations of Ibuprofenate (RuIbp) and Naproxenate (RuNpx) metallodrugs were synthesized and characterized. The procedure rationally designed to avoid
Tian Zhang et al.
Advanced healthcare materials, 8(18), e1900543-e1900543 (2019-07-28)
Patients with brain metastases of triple negative breast cancer (TNBC) have a poor prognosis owing to the lack of targeted therapies, the aggressive nature of TNBC, and the presence of the blood-brain barrier (BBB) that blocks penetration of most drugs.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service